Markets Update: Investors Anticipate Next Week’s US Election

Episode Summary

Executive Summary: Amelia Garnett says clients are focused on two macro catalysts: the U.S. election and the vaccine. Markets largely expect a Democratic sweep, but the key debate is how much Senate control Democrats gain and whether fiscal stimulus comes before tax hikes. Investors are positioned bullishly for a vaccine-plus-blue-wave scenario, favoring U.S. equities, EM, lower dollar trades, selected commodities, and higher yields, while watching for election disruption and worsening COVID as the main risks.

Main Topics: Election outlook and policy implications (Priority: 5/5): Clients expect a Democratic win across the presidency and Congress, but uncertainty remains around polling error and Senate seat count, which will determine whether Democrats can pass fiscal stimulus and potentially pursue broader policy changes. Vaccine timeline and COVID trajectory (Priority: 5/5): Markets are increasingly driven by the need for vaccine progress amid rising cases and tighter lockdowns; investors are watching late-2020 trial data and possible FDA requests, with broad circulation expected in 2021. Cross-asset positioning for a blue wave plus vaccine (Priority: 4/5): Clients are generally bullish and positioned for cyclical reflation: long equities, especially U.S. assets; open to EM; supportive of lower-dollar trades; and constructive on commodities and rates themes tied to growth and inflation. Currency views and the dollar outlook (Priority: 4/5): The lower-dollar trade remains popular, but with Europe weakening, clients are looking for alternative expressions such as long Chinese yuan, supported by China’s relative growth strength and higher carry. Rates and inflation repricing (Priority: 4/5): Markets are pricing a first Fed hike in 2024, but a stronger growth/inflation backdrop from a vaccine and fiscal expansion could pull that forward and steepen the yield curve. Key market risks and election-night timing (Priority: 5/5): The main short-term risk is a contested election, while the broader risk is a prolonged COVID shock. Traders are focusing on early-reporting states and the possibility that Senate control may not be settled until a Georgia runoff in January.

Key Arguments: The market consensus is a Democratic sweep, but the size of the Senate majority matters more than the headline result for policy and markets. A blue wave is no longer viewed solely as a tax-hike risk; investors increasingly see it as the best route to a large fiscal package, with fiscal likely arriving before tax changes. Vaccines are the key medium-term market catalyst, especially after a difficult week of rising cases and European lockdowns. Most clients are positioned bullishly for a reflation trade, favoring equities, cyclical assets, and higher yields if vaccine progress and fiscal stimulus align. The U.S. dollar remains under pressure, but clients are broadening away from the euro trade toward the Chinese yuan because of China’s outperformance and carry advantage. Oil, copper, gold, and silver are seen as beneficiaries of reopening, industrial recovery, and higher inflation expectations. A contested election could trigger near-term market indigestion, but the more durable risk is COVID extending the timeline for normalization and undermining both health and economic growth.

Data Points: U.S. election timing: 5 days away - The discussion is taking place shortly before the 2020 U.S. presidential election. Democratic Senate threshold: 51 seats - With 51 seats, Democrats could pass fiscal policy more easily. Democratic Senate supermajority scenario: 53 or 54 seats - Could enable eliminating the filibuster and pursuing broader policy changes. Vaccine trial timing: November 2020 - Pfizer, Moderna, and possibly Oxford/AstraZeneca were expected to release phase 3 data. Possible FDA approval request: December 2020 - Data could lead to FDA approval requests after November trial results. U.S. vaccine circulation expectation: First quarter of 2021, maybe March - Client expectation for broad circulation in the United States. Europe vaccine circulation expectation: Summer 2021 - Broader rollout in Europe expected later than in the U.S. Fed first hike pricing: Mid-2024 - Current market pricing for the first Fed rate hike. Potentially revised Fed hike timing: 2023 - Could be pulled forward if vaccine and blue wave drive growth and inflation. Election-night states to watch: 3 states - Florida, North Carolina, and Ohio are highlighted for early results. Biden win conditional probability if he wins key states: ~99% - According to 538/Nate Silver model, if Biden wins any of the three key states. Senate runoff timing: January 5 - Georgia runoff could determine final Senate control.

Pivotal Quotes: "it all comes down to two things. The first is the election... And two, the vaccine, which will dictate the future path of COVID." — Amelia Garnett: Opening framework for the two dominant macro drivers clients are focused on. "if we do get this combination of a vaccine and we get the blue sweep, that's a pretty powerful cocktail for the economy and cyclical assets more broadly." — Amelia Garnett: Describing the bullish market setup under a vaccine-plus-Democratic-sweep scenario. "the biggest risk out there is that of COVID." — Amelia Garnett: Identifying the most important downside risk beyond the election itself.

Implications: Investors are likely to keep leaning into reflation and reopening trades, but election-night volatility and COVID headlines could quickly reverse positioning. The medium-term direction depends on whether stimulus, vaccine rollout, and growth expectations improve together.